KR20060130661A - 에어로졸화 항응고제의 사용을 통해 페 조직에서 피브린응고를 예방하는 방법 - Google Patents

에어로졸화 항응고제의 사용을 통해 페 조직에서 피브린응고를 예방하는 방법 Download PDF

Info

Publication number
KR20060130661A
KR20060130661A KR1020067019275A KR20067019275A KR20060130661A KR 20060130661 A KR20060130661 A KR 20060130661A KR 1020067019275 A KR1020067019275 A KR 1020067019275A KR 20067019275 A KR20067019275 A KR 20067019275A KR 20060130661 A KR20060130661 A KR 20060130661A
Authority
KR
South Korea
Prior art keywords
heparin
atiii
lung injury
antithrombin iii
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020067019275A
Other languages
English (en)
Korean (ko)
Inventor
페렌렐이 엔크바아타르
가즈노리 무라카미
다니엘 엘. 트래버
Original Assignee
지티씨바이오쎄라퓨틱스,인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 지티씨바이오쎄라퓨틱스,인크. filed Critical 지티씨바이오쎄라퓨틱스,인크.
Publication of KR20060130661A publication Critical patent/KR20060130661A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020067019275A 2004-02-20 2005-02-15 에어로졸화 항응고제의 사용을 통해 페 조직에서 피브린응고를 예방하는 방법 Ceased KR20060130661A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US54623604P 2004-02-20 2004-02-20
US60/546,236 2004-02-20
US11/057,522 2005-02-14
US11/057,522 US20050192226A1 (en) 2004-02-20 2005-02-14 Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020097027466A Division KR20100017971A (ko) 2004-02-20 2005-02-15 에어로졸화 항응고제의 사용을 통해 폐 조직에서 피브린 응고를 예방하는 방법

Publications (1)

Publication Number Publication Date
KR20060130661A true KR20060130661A (ko) 2006-12-19

Family

ID=34889863

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020067019275A Ceased KR20060130661A (ko) 2004-02-20 2005-02-15 에어로졸화 항응고제의 사용을 통해 페 조직에서 피브린응고를 예방하는 방법
KR1020097027466A Abandoned KR20100017971A (ko) 2004-02-20 2005-02-15 에어로졸화 항응고제의 사용을 통해 폐 조직에서 피브린 응고를 예방하는 방법
KR1020117015353A Ceased KR20110084555A (ko) 2004-02-20 2005-02-15 에어로졸화 항응고제의 사용을 통해 폐 조직에서 피브린 응고를 예방하는 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020097027466A Abandoned KR20100017971A (ko) 2004-02-20 2005-02-15 에어로졸화 항응고제의 사용을 통해 폐 조직에서 피브린 응고를 예방하는 방법
KR1020117015353A Ceased KR20110084555A (ko) 2004-02-20 2005-02-15 에어로졸화 항응고제의 사용을 통해 폐 조직에서 피브린 응고를 예방하는 방법

Country Status (10)

Country Link
US (2) US20050192226A1 (https=)
EP (2) EP1725244B1 (https=)
JP (2) JP2007533657A (https=)
KR (3) KR20060130661A (https=)
AT (1) ATE493135T1 (https=)
AU (1) AU2005216044B2 (https=)
CA (1) CA2557411A1 (https=)
DE (1) DE602005025610D1 (https=)
IL (1) IL177588A0 (https=)
WO (1) WO2005081816A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2480790A1 (en) * 2002-04-01 2003-10-16 Kazunori Murakami Use of antithrombin iii in treating acute lung injury
US20050169908A1 (en) * 2004-01-23 2005-08-04 Kazunori Murakami Use of aerosolized antithrombin to treat acute lung injury
US20050192226A1 (en) * 2004-02-20 2005-09-01 Perenlei Enkhbaatar Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants
US20050245444A1 (en) * 2004-04-30 2005-11-03 Yann Echelard Method of using recombinant human antithrombin for neurocognitive disorders
US20060121004A1 (en) * 2004-12-07 2006-06-08 Yann Echelard Methods of reducing the incidence of rejection in tissue transplantation through the use of recombinant human antithrombin
ES2811526T3 (es) 2010-12-30 2021-03-12 Lab Francais Du Fractionnement Glicoles como agentes de inactivación de patógenos
WO2014089327A1 (en) * 2012-12-05 2014-06-12 National Jewish Health Treatment for airway cast obstruction
EP3594230A1 (en) 2013-02-13 2020-01-15 Laboratoire Français du Fractionnement et des Biotechnologies Highly galactosylated anti-tnf-alpha antibodies and uses thereof
US10034921B2 (en) 2013-02-13 2018-07-31 Laboratoire Français Du Fractionnement Et Des Biotechnologies Proteins with modified glycosylation and methods of production thereof
EP3016729B1 (fr) 2013-07-05 2020-03-25 Laboratoire Francais du Fractionnement et des Biotechnologies Societe Anonyme Matrice de chromatographie d'affinité
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127347A (en) * 1994-01-12 2000-10-03 Univ Michigan Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes
US6355626B1 (en) * 1994-05-13 2002-03-12 The Trustees Of The University Of Pennsylvania Antithrombin agents in treatment of asthma
US5843705A (en) * 1995-02-21 1998-12-01 Genzyme Transgenic Corporation Transgenically produced antithrombin III
US7045585B2 (en) * 1995-11-30 2006-05-16 Hamilton Civic Hospital Research Development Inc. Methods of coating a device using anti-thrombin heparin
US6063593A (en) * 1996-11-12 2000-05-16 University Of Southern California University Park Campus TGFβ1 responsive bone marrow derived cells to express a recombinant protein
US6124257A (en) * 1997-08-28 2000-09-26 Lezdey; John Method of treatment
AU2440802A (en) * 2000-10-18 2002-04-29 Massachusetts Inst Technology Methods and products related to pulmonary delivery of polysaccharides
DE10132307A1 (de) 2001-07-06 2003-01-30 Aventis Behring Gmbh Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS
CA2480790A1 (en) * 2002-04-01 2003-10-16 Kazunori Murakami Use of antithrombin iii in treating acute lung injury
US20050169908A1 (en) * 2004-01-23 2005-08-04 Kazunori Murakami Use of aerosolized antithrombin to treat acute lung injury
US20050192226A1 (en) * 2004-02-20 2005-09-01 Perenlei Enkhbaatar Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants

Also Published As

Publication number Publication date
WO2005081816A3 (en) 2007-02-01
EP1725244A4 (en) 2009-08-12
EP1725244B1 (en) 2010-12-29
DE602005025610D1 (de) 2011-02-10
WO2005081816A2 (en) 2005-09-09
US20110070167A1 (en) 2011-03-24
US20050192226A1 (en) 2005-09-01
JP2007533657A (ja) 2007-11-22
ATE493135T1 (de) 2011-01-15
EP2322189A2 (en) 2011-05-18
KR20100017971A (ko) 2010-02-16
KR20110084555A (ko) 2011-07-25
AU2005216044A1 (en) 2005-09-09
JP2011162555A (ja) 2011-08-25
AU2005216044B2 (en) 2011-07-14
CA2557411A1 (en) 2005-09-09
EP1725244A2 (en) 2006-11-29
IL177588A0 (en) 2008-03-20
EP2322189A3 (en) 2011-07-27

Similar Documents

Publication Publication Date Title
US20110070167A1 (en) Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants
KR20060127992A (ko) 급성 폐 손상을 치료하기 위한 에어로졸화 항트롬빈의 용도
KR20090114341A (ko) Ｆｇｆ2를 유효성분으로 포함하는 천식 및 만성폐쇄성 폐질환 예방 또는 치료제
JP2015502370A (ja) 炎症性疾患の治療のための組換えヒトα１−抗トリプシン
US20060121004A1 (en) Methods of reducing the incidence of rejection in tissue transplantation through the use of recombinant human antithrombin
EP1390407B1 (en) The lectin-like domain of thrombomodulin and its therapeutic use
KR102772403B1 (ko) 알파-1 안티 트립신 결핍증 z 타입 돌연변이의 교정을 위한 프라임에디팅 가이드 rna를 포함하는 프라임에딩팅용 조성물
Turner Alpha-1 antitrypsin deficiency: new developments in augmentation and other therapies
US20050245444A1 (en) Method of using recombinant human antithrombin for neurocognitive disorders
US20150071909A1 (en) Methods and compositions for reducing the incidence of post-surgical adhesions
AU2011202575A1 (en) Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants
CN1946419A (zh) 使用气溶胶化抗凝血酶治疗急性肺损伤
AU2002312938B2 (en) The lectin-like domain of thrombomodulin and its therapeutic use
US20110294733A1 (en) Modified human thrombopoietin polypeptide fragment and manufacturing method thereof
JP2025516000A (ja) Ｆｇｆ５の転写体変異体－２及びそのタンパク質の肝線維症の予防、抑制、及び治療用途
CN116920093A (zh) Mmp9抑制剂及mmp9缺陷型树突状细胞及其抗炎作用
WO2005112968A2 (en) Method of using recombinant human antithrombin for neurocognitive disorders
AU2002312938A1 (en) The lectin-like domain of thrombomodulin and its therapeutic use

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20060919

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20070122

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20071126

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20080521

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20090831

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20080521

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20071126

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20091201

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20090831

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20100506

Appeal identifier: 2009101010968

Request date: 20091201

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20091230

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20100430

WITB Written withdrawal of application
J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20091201

Effective date: 20100506

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20100506

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20091201

Decision date: 20100506

Appeal identifier: 2009101010968